Committee Decisions
Committee List
- ASPH DTC
- Commissioning Intentions
- East Surrey CCG Medicines Programme Board
- East Surrey ICP MOG
- Epsom St Helier NDAIG
- ESCCG sub-committee of North Place Alliance Clinical Strategy Committee (formerly Clinical Executive
- Guildford and Waverley MOG
- Medicines Optimisation Operational Group (MOOG)
- Not Set
- NW Surrey CCG Medicines Optimisation Group
- Primary Care Medicines Optimisation Clinical reference Group (PCMOCRG)
- RSCH DTC
- Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
- Surrey Downs CCG MOG
- Surrey Downs CCG Prescribing Leads Meeting
- Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
- Surrey Heartlands Medicines Optimisation Board (MOB)
- Surrey Heartlands Medicines Safety Committee (MSC)
- Surrey Medicines Commissioners Group
- Surrey Priorities Committee
Decisions : Epsom St Helier NDAIG
Records returned : 4.
Date
Drug Profile
Narrative
Traffic Light Status
Wednesday, October 2, 2019
SDCCG / Epsom & St Helier - LOCAL RECOMMENDATION
Epsom & St Helier have produced guidance on the identification and management of Polymyalgia Rheumatica for the GPs of Surrey Downs CCG
N/A
Wednesday, October 11, 2017
SDCCG and EPSOM ST HELIER - RED STATUS
The New Drugs & Interface Committee agreed that Ferracru (Ferric maltol) is available to be prescribed in the Trust by consultant gastroenterologists (or gastroenterology Specialist registrars under the guidance of gastro consultants) in IBD patients only. It has a place as an oral iron therapy in patients intolerant to at least one oral ferrous iron salt as an alternative to iv iron therapy. It is usually prescribed for 2-3 months from secondary care
The New Drugs & Interface Committee agreed that Ferracru (Ferric maltol) is available to be prescribed in the Trust by consultant gastroenterologists (or gastroenterology Specialist registrars under the guidance of gastro consultants) in IBD patients only. It has a place as an oral iron therapy in patients intolerant to at least one oral ferrous iron salt as an alternative to iv iron therapy. It is usually prescribed for 2-3 months from secondary care
See Below
Wednesday, April 13, 2016
Epsom & St Helier LOCAL DECISION
BLACK drug
The committee agreed that the evidence base using vitamin B12 injections to help improve the symptoms of Chronic Fatigue Syndrome (CFS) and Myalgic Encephalopathy (ME)was weak, long term safety was unknown and the treatment of CFS and ME with vitamin B12 was not currently supported by NICE.
The request to use it in the Trust or to recommend GP’s prescribe vitamin B12 in this patient cohort was rejected.
However it was recognised that a trial would be useful in strengthening the evidence base.
BLACK drug
The committee agreed that the evidence base using vitamin B12 injections to help improve the symptoms of Chronic Fatigue Syndrome (CFS) and Myalgic Encephalopathy (ME)was weak, long term safety was unknown and the treatment of CFS and ME with vitamin B12 was not currently supported by NICE.
The request to use it in the Trust or to recommend GP’s prescribe vitamin B12 in this patient cohort was rejected.
However it was recognised that a trial would be useful in strengthening the evidence base.
See Below
Wednesday, February 20, 2013
Shared care documentation approved
Amber